Leerink Partners Believes Thermo Fisher (NYSE: TMO) Won’t Stop Here

Leerink Partners analyst Puneet Souda maintained a Buy rating on Thermo Fisher (TMOResearch Report) on July 28 and set a price target of $600.00. The company’s shares closed last Friday at $540.01, close to its 52-week high of $543.30.

According to TipRanks.com, Souda is a 5-star analyst with an average return of 18.8% and a 66.1% success rate. Souda covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, AbCellera Biologics, and Castle Biosciences.

Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $586.78, a 9.7% upside from current levels. In a report issued on July 16, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $580.00 price target.

See today’s analyst top recommended stocks >>

Thermo Fisher’s market cap is currently $212.2B and has a P/E ratio of 25.00. The company has a Price to Book ratio of -86.98.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services segments. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.